Terhi Kurko

Dr. Terhi Kurko

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2015 in European Psychiatry
Verified
Journal Article
Closed access
TKTerhi Kurko
Terhi Kurko
LSL.K. Saastamoinen
L.K. Saastamoinen
STS. Tähkäpää
S. Tähkäpää
ATA. Tuulio-Henriksson
A. Tuulio-Henriksson
TTT. Taiminen
T. Taiminen
JHJ. Hietala
J. Hietala
Background: Numerous treatment guidelines recommend that long-term use of benzodiazepines (BZD) should be avoided primarily due to development of tolerance and a risk for BZD dependence. Despite this, long-term BZD use remains a controversial subject in clinical patient care with “for and against” debates. However, there is no explicit understanding of what is meant by long-term BZD use in real world. The aim of this study was to assess different definitions, usage patterns, prevalence and other characteristics of long-term BZD use based on published register-based studies. Synthesis of these characteristics is essential to derive a meaningful definition of long-term BZD.Methods: Systematic review of register-based studies on long-term BZD use published in 1994–2014.Results: Fourty-one studies met our predetermined inclusion criteria. The length of BZD use defined as “long-term” varied in these studies ranging from one month to several years. The most common definition was six months or longer during a year. The prevalence of long-term BZD use in the general population was estimated to be about 3%. The relative proportion of long-term BZD users (all definitions) in adult BZD users ranged from 6% to 76% (mean 24%; 95% CL 13–36%). The estimates were higher in studies only on the elderly (47%; 95% CL 31–64%). Long-term use involved typically steady treatment with low BZD doses. However, in elderly patients long-term BZD use and exceeding recommended doses was relatively common. Several characteristics associated with long-term use were found.Conclusions: Long-term BZD use is common and a clinical reality. Uniform definitions for “long-term”, which is in line with population-based evidence, is needed to have more comparable results between studies. Our systematic review suggests that duration of BZD treatment over six months, the most common definition for long-term BZD use in the included studies. As also recommended previously, it is a useful starting point for further analyses on disadvantages but also potential advantages associated with long-term BZD use.

4 May 2018 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
TKTerhi Kurko
Terhi Kurko
LSLeena K. Saastamoinen
Leena K. Saastamoinen
ATAnnamari Tuulio‐Henriksson
Annamari Tuulio‐Henriksson
TTTero Taiminen
Tero Taiminen
JTJari Tiihonen
Jari Tiihonen
JHJarmo Hietala
Jarmo Hietala

29 July 2010 in BMC Public Health
Verified
Journal Article
Open access
PDF file
TKTerhi Kurko
Terhi Kurko
KLKari Linden
Kari Linden
KPKirsi Pietilä
Kirsi Pietilä
PSPatrick Sandström
Patrick Sandström
MAMarja Airaksinen
Marja Airaksinen
Guidelines on smoking cessation (SC) emphasize healthcare cooperation and community pharmacists' involvement. This study explored the familiarity and implementation of the National SC Guideline in Finnish community pharmacies, factors relating to Guideline familiarity, implementation and provision of SC services.

1 September 2021 in Health Policy
Verified
Journal Article
Open access
HRHanna Rättö
Hanna Rättö
TKTerhi Kurko
Terhi Kurko
JMJaana E. Martikainen
Jaana E. Martikainen
KAKatri Aaltonen
Katri Aaltonen
International literature suggests that co-payment increases are associated with decreased medicine use, although the effects depend on context. We examined the impact of a co-payment increase on the consumption of type 2 antidiabetics in Finland, a country with a comprehensive health and social security system including ceiling mechanisms aiming to protect patients from high co-payment expenditures. We used administrative register data on all reimbursed purchases of antidiabetics during 2014-2018. An interrupted time series design with segmented regression was used to examine the mean monthly purchase per person, measured as Defined Daily Doses (DDDs), before and after the co-payment increase. At baseline, the mean monthly purchase per person of type 2 antidiabetics was 105 DDDs (95% CI 103.8; 106.0;p<0.001) and there was a decreasing trend of 0.2 DDDs per month (95% CI -0.23;-0.13;p<0.001). A statistically significant decrease of 5.6 DDDs (95% CI -7.3;-3.8;p<0.001) was detected after the reform; however, no significant change in the trend was observed. No significant increase was detected in the mean monthly per person purchase of insulins. The results suggest that a co-payment increase decreases consumption of necessary medicines despite the presence of a medicine co-payment ceiling mechanism. Whether the decrease was associated with negative health effects remains to be further investigated.

1 August 2009 in Health Policy
Verified
Journal Article
Closed access
TKTerhi Kurko
Terhi Kurko
KLKari Linden
Kari Linden
MVMari Vasama
Mari Vasama
KPKirsi Pietilä
Kirsi Pietilä
MAMarja Airaksinen
Marja Airaksinen

8 October 2014 in Health Expectations
Verified
Journal Article
Closed access
PDF file
TKTerhi Kurko
Terhi Kurko
KLKari Linden
Kari Linden
MKMaija Kolstela
Maija Kolstela
KPKirsi Pietilä
Kirsi Pietilä
MAMarja Airaksinen
Marja Airaksinen